Ultragenyx Email Format
Biotechnology Research
・
1,001-2,500 employees
・
Novato, CA, USA
Ultragenyx is a biotechnology company focused on developing and commercializing novel therapies for rare and ultrarare genetic diseases with high unmet medical needs.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@ultragenyx.com
Company Overview
Industry
Biotechnology Research
Founded
2010
Headquarters
Novato, CA, USA
Revenue
$500M-$1B
FUNDING Stage
Public
Website
Key Executives
Emil D. Kakkis (Founder, President and Chief Executive Officer), Howard Horn (Chief Financial Officer and Executive Vice President, Corporate Strategy), Dennis Huang (Chief Technical Operations Officer and Executive Vice President, Gene Therapy Research and Development)
Tech Stack
Veeva Vault
Quality Management / Life Sciences Cloud
Signup
to know
Signup
to know
Signup
to know
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Ultragenyx?
Ultragenyx uses the firstinitiallast format, so Jane Smith would be jsmith@ultragenyx.com.
What approved medicines does Ultragenyx currently sell for rare bone diseases?
Ultragenyx markets Crysvita for X-linked hypophosphatemia, a rare bone disease, and it is the company's top-selling product with 2026 full-year revenue guidance of $500 million to $520 million.
How many employees does Ultragenyx have and where is the company headquartered?
Ultragenyx is headquartered in Novato, California and employs approximately 1,517 people. Tools like Clay can help you identify and reach specific contacts there when building a prospecting list.
Which gene therapy programs does Ultragenyx have under FDA review in 2026?
Ultragenyx has two gene therapy BLAs under FDA review in 2026: DTX401 for glycogen storage disease type Ia and DTX301 for OTC deficiency, with DTX401 having received Priority Review designation.
Who founded Ultragenyx and what role does that person hold today?
Emil D. Kakkis founded Ultragenyx and continues to serve as President and Chief Executive Officer, guiding the company's mission to develop treatments for rare and ultrarare genetic diseases.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating